{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:20:38Z","timestamp":1791822038587,"version":"4.3.4"},"reference-count":65,"publisher":"Walter de Gruyter GmbH","issue":"2","license":[{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Fragile X syndrome (FXS) is a genetic disorder caused by a mutation in the\n                    <jats:italic>FMR1<\/jats:italic>\n                    gene on the X chromosome, leading to a range of developmental and intellectual disabilities. FXS is characterized by intellectual disability, behavior challenges, and distinct physical features such as an elongated face, large ears, and hyperflexible joints; FXS remains the most common inherited cause of intellectual disability. Behavioral manifestations often include attention deficits, hyperactivity, anxiety, and features of autism spectrum disorder. The prevalence of FXS in the South Asian population is not well-documented, but existing studies suggest it may be comparable to global prevalence rates, which are approximately 1 in 4,000 males and 1 in 8,000 females. Accurate diagnosis of FXS in South Asians is crucial due to the implications for early intervention and treatment, which can significantly improve the quality of life and developmental outcomes for affected individuals. Early diagnosis also facilitates genetic counselling and family planning, helping to reduce the risk of recurrence in families. Increased awareness and screening in South Asian communities are essential to address the diagnostic gap and ensure timely support for individuals with FXS or disorders associated with the premutation of\n                    <jats:italic>FMR1.<\/jats:italic>\n                  <\/jats:p>","DOI":"10.1515\/mr-2024-0060","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T15:27:16Z","timestamp":1732807636000},"page":"164-173","source":"Crossref","is-referenced-by-count":4,"title":["Prevalence of fragile X syndrome in South Asia, and importance of diagnosis"],"prefix":"10.1515","volume":"5","author":[{"given":"Aminath","family":"Fazna","sequence":"first","affiliation":[{"name":"Indira Gandhi Memorial Hospital , Male , Maldives"},{"name":"MIND Institute, University of California Davis , Sacramento , CA , USA"},{"name":"Department of Pediatrics , University of California Davis Health , Sacramento , CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5029-8448","authenticated-orcid":false,"given":"Randi Jenssen","family":"Hagerman","sequence":"additional","affiliation":[{"name":"MIND Institute, University of California Davis , Sacramento , CA , USA"},{"name":"Department of Pediatrics , University of California Davis Health , Sacramento , CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2024,11,29]]},"reference":[{"key":"2026040923062353328_j_mr-2024-0060_ref_001","unstructured":"Stone, WL, Basit, H, Shah, M, Los, E. Fragile X syndrome; 2024."},{"key":"2026040923062353328_j_mr-2024-0060_ref_002","doi-asserted-by":"crossref","unstructured":"Hagerman, RJ, Berry-Kravis, E, Kaufmann, WE, Ono, MY, Tartaglia, N, Lachiewicz, A, et al.. Advances in the treatment of fragile X syndrome. Pediatrics 2009;123:378\u201390. https:\/\/doi.org\/10.1542\/peds.2008-0317.","DOI":"10.1542\/peds.2008-0317"},{"key":"2026040923062353328_j_mr-2024-0060_ref_003","doi-asserted-by":"crossref","unstructured":"Hagerman, RJ, Hagerman, PJ. Fragile X syndrome. In: Outcomes in neurodevelopmental and genetic disorders. Cambridge: Cambridge University Press; 2002:198\u2013219 pp.","DOI":"10.1017\/CBO9780511543876.009"},{"key":"2026040923062353328_j_mr-2024-0060_ref_004","doi-asserted-by":"crossref","unstructured":"Tassone, F, Iong, K, Tong, TH, Lo, J, Gane, LW, Berry-Kravis, E, et al.. FMR1 CGG allele size and prevalence ascertained through newborn screening in the United States. Genome Med 2012;4:100. https:\/\/doi.org\/10.1186\/gm401.","DOI":"10.1186\/gm401"},{"key":"2026040923062353328_j_mr-2024-0060_ref_005","doi-asserted-by":"crossref","unstructured":"Seltzer, MM, Baker, MW, Hong, J, Maenner, M, Greenberg, J, Mandel, D. Prevalence of CGG expansions of the FMR1 gene in a US population\u2010based sample. Am J Med Genet B Neuropsychiatr Genet 2012;159B:589\u201397. https:\/\/doi.org\/10.1002\/ajmg.b.32065.","DOI":"10.1002\/ajmg.b.32065"},{"key":"2026040923062353328_j_mr-2024-0060_ref_006","doi-asserted-by":"crossref","unstructured":"Hagerman, R. Molecular advances leading to treatment implications for fragile X premutation carriers. Brain Disord Ther 2014;03. https:\/\/doi.org\/10.4172\/2168-975x.1000119.","DOI":"10.4172\/2168-975X.1000119"},{"key":"2026040923062353328_j_mr-2024-0060_ref_007","doi-asserted-by":"crossref","unstructured":"Maddalena, A, Richards, CS, McGinniss, MJ, Brothman, A, Desnick, RJ, Grier, RE, et al.. Technical standards and guidelines for fragile X: the first of a series of disease- specific supplements to the standards and guidelines for clinical genetics laboratories of the American College of medical genetics. Genet Med 2001;3:200\u20135. https:\/\/doi.org\/10.1097\/00125817-200105000-00010.","DOI":"10.1097\/00125817-200105000-00010"},{"key":"2026040923062353328_j_mr-2024-0060_ref_008","doi-asserted-by":"crossref","unstructured":"Polussa, J, Schneider, A, Hagerman, R. Molecular advances leading to treatment implications for fragile X premutation carriers. Brain Disord Ther 2014;03. https:\/\/doi.org\/10.4172\/2168-975x.1000119.","DOI":"10.4172\/2168-975X.1000119"},{"key":"2026040923062353328_j_mr-2024-0060_ref_009","doi-asserted-by":"crossref","unstructured":"Bartholomay, K, Lee, C, Bruno, J, Lightbody, A, Reiss, A. Closing the gender gap in fragile X syndrome: review of females with fragile X syndrome and preliminary research findings. Brain Sci 2019;9:11. https:\/\/doi.org\/10.3390\/brainsci9010011.","DOI":"10.3390\/brainsci9010011"},{"key":"2026040923062353328_j_mr-2024-0060_ref_010","doi-asserted-by":"crossref","unstructured":"Nolin, SL, Glicksman, A, Houck, GE, Brown, WT, Dobkin, CS. Mosaicism in fragile X affected males. Am J Med Genet 1994;51:509\u201312. https:\/\/doi.org\/10.1002\/ajmg.1320510444.","DOI":"10.1002\/ajmg.1320510444"},{"key":"2026040923062353328_j_mr-2024-0060_ref_011","doi-asserted-by":"crossref","unstructured":"Hunter, J, Rivero\u2010Arias, O, Angelov, A, Kim, E, Fotheringham, I, Leal, J. Epidemiology of fragile X syndrome: a systematic review and meta\u2010analysis. Am J Med Genet A 2014;164:1648\u201358. https:\/\/doi.org\/10.1002\/ajmg.a.36511.","DOI":"10.1002\/ajmg.a.36511"},{"key":"2026040923062353328_j_mr-2024-0060_ref_012","doi-asserted-by":"crossref","unstructured":"Raspa, M, Wheeler, AC, Riley, C. Public health literature review of fragile X syndrome. Pediatrics 2017;139:S153\u201371. https:\/\/doi.org\/10.1542\/peds.2016-1159c.","DOI":"10.1542\/peds.2016-1159C"},{"key":"2026040923062353328_j_mr-2024-0060_ref_013","doi-asserted-by":"crossref","unstructured":"Henderson, C, Evans-Lacko, S, Thornicroft, G. Mental illness stigma, help seeking, and public health programs. Am J Publ Health 2013;103:777\u201380. https:\/\/doi.org\/10.2105\/ajph.2012.301056.","DOI":"10.2105\/AJPH.2012.301056"},{"key":"2026040923062353328_j_mr-2024-0060_ref_014","doi-asserted-by":"crossref","unstructured":"Charalsawadi, C, Wirojanan, J, Jaruratanasirikul, S, Ruangdaraganon, N, Geater, A, Limprasert, P. Common clinical characteristics and rare medical problems of fragile X syndrome in Thai patients and review of the literature. Int J Pediatr 2017;2017:9318346. https:\/\/doi.org\/10.1155\/2017\/9318346.","DOI":"10.1155\/2017\/9318346"},{"key":"2026040923062353328_j_mr-2024-0060_ref_015","doi-asserted-by":"crossref","unstructured":"Peprah, E. Fragile X syndrome: the FMR1 CGG repeat distribution among world populations. Ann Hum Genet 2012;76:178\u201391. https:\/\/doi.org\/10.1111\/j.1469-1809.2011.00694.x.","DOI":"10.1111\/j.1469-1809.2011.00694.x"},{"key":"2026040923062353328_j_mr-2024-0060_ref_016","doi-asserted-by":"crossref","unstructured":"Bartholomay, K, Lee, C, Bruno, J, Lightbody, A, Reiss, A. Closing the gender gap in fragile X syndrome: review of females with fragile X syndrome and preliminary research findings. Brain Sci 2019;9:11. https:\/\/doi.org\/10.3390\/brainsci9010011.","DOI":"10.3390\/brainsci9010011"},{"key":"2026040923062353328_j_mr-2024-0060_ref_017","doi-asserted-by":"crossref","unstructured":"Brand, BA, Blesson, AE, Smith-Hicks, CL. The impact of X-chromosome inactivation on phenotypic expression of X-linked neurodevelopmental disorders. Brain Sci 2021;11:904. https:\/\/doi.org\/10.3390\/brainsci11070904.","DOI":"10.3390\/brainsci11070904"},{"key":"2026040923062353328_j_mr-2024-0060_ref_018","doi-asserted-by":"crossref","unstructured":"Crawford, DC, Meadows, KL, Newman, JL, Taft, LF, Scott, E, Leslie, M, et al.. Prevalence of the fragile X syndrome in african-Americans. Am J Med Genet 2002;110:226\u201333. https:\/\/doi.org\/10.1002\/ajmg.10427.","DOI":"10.1002\/ajmg.10427"},{"key":"2026040923062353328_j_mr-2024-0060_ref_019","doi-asserted-by":"crossref","unstructured":"Strom, CM, Crossley, B, Redman, JB, Buller, A, Quan, F, Peng, M, et al.. Molecular testing for Fragile X Syndrome: lessons learned from 119,232 tests performed in a clinical laboratory. Genet Med 2007;9:46\u201351. https:\/\/doi.org\/10.1097\/gim.0b013e31802d833c.","DOI":"10.1097\/GIM.0b013e31802d833c"},{"key":"2026040923062353328_j_mr-2024-0060_ref_020","doi-asserted-by":"crossref","unstructured":"Pesso, R, Berkenstadt, M, Cuckle, H, Gak, E, Peleg, L, Frydman, M, et al.. Screening for fragile X syndrome in women of reproductive age. Prenat Diagn 2000;20:611\u20134. https:\/\/doi.org\/10.1002\/1097-0223(200008)20:8<611::aid-pd881>3.0.co;2-m.","DOI":"10.1002\/1097-0223(200008)20:8<611::AID-PD881>3.0.CO;2-M"},{"key":"2026040923062353328_j_mr-2024-0060_ref_021","doi-asserted-by":"crossref","unstructured":"Crawford, DC, Acu\u00f1a, JM, Sherman, SL. FMR1 and the fragile X syndrome: human genome epidemiology review. Genet Med 2001;3:359\u201371. https:\/\/doi.org\/10.1097\/00125817-200109000-00006.","DOI":"10.1097\/00125817-200109000-00006"},{"key":"2026040923062353328_j_mr-2024-0060_ref_022","unstructured":"de Vries, BB, Wiegers, AM, Smits, AP, Mohkamsing, S, Duivenvoorden, HJ, Fryns, JP, et al.. Mental status of females with an FMR1 gene full mutation. Am J Hum Genet 1996;58:1025\u201332."},{"key":"2026040923062353328_j_mr-2024-0060_ref_023","doi-asserted-by":"crossref","unstructured":"Guo, Q, Chang, YY, Huang, CH, Hsiao, YS, Hsiao, YC, Chiu, IF, et al.. Population-based carrier screening and prenatal diagnosis of fragile X syndrome in East Asian populations. J Genet Genomics 2021;48:1104\u201310. https:\/\/doi.org\/10.1016\/j.jgg.2021.04.012.","DOI":"10.1016\/j.jgg.2021.04.012"},{"key":"2026040923062353328_j_mr-2024-0060_ref_024","doi-asserted-by":"crossref","unstructured":"Pouya, AR, Abedini, SS, Mansoorian, N, Behjati, F, Nikzat, N, Mohseni, M, et al.. Fragile X syndrome screening of families with consanguineous and non-consanguineous parents in the Iranian population. Eur J Med Genet 2009;52:170\u20133. https:\/\/doi.org\/10.1016\/j.ejmg.2009.03.014.","DOI":"10.1016\/j.ejmg.2009.03.014"},{"key":"2026040923062353328_j_mr-2024-0060_ref_025","doi-asserted-by":"crossref","unstructured":"Demirhan, O, Tastemir, D, Diler, RS, Firat, S, Avci, A. A cytogenetic study in 120 Turkish children with intellectual disability and characteristics of fragile X syndrome. Yonsei Med J 2003;44:583. https:\/\/doi.org\/10.3349\/ymj.2003.44.4.583.","DOI":"10.3349\/ymj.2003.44.4.583"},{"key":"2026040923062353328_j_mr-2024-0060_ref_026","unstructured":"Arrieta, I, Criado, B, Martinez, B, Telez, M, Nu\u00f1ez, T, Pe\u00f1agarikano, O, et al.. A survey of fragile X syndrome in a sample from Spanish Basque country. Ann Genet 1999;42:197\u2013201."},{"key":"2026040923062353328_j_mr-2024-0060_ref_027","doi-asserted-by":"crossref","unstructured":"Hecimovic, S, Tarnik, IP, Baric, I, \u010ckarun, \u017d, Pavelic, K. Screening for fragile X syndrome: results from a school for mentally retarded children. Acta Paediatr 2002;91:535\u20139. https:\/\/doi.org\/10.1111\/j.1651-2227.2002.tb03273.x.","DOI":"10.1111\/j.1651-2227.2002.tb03273.x"},{"key":"2026040923062353328_j_mr-2024-0060_ref_028","doi-asserted-by":"crossref","unstructured":"Mundhofir, FE. Prevalence of fragile X syndrome in males and females in Indonesia. World J Med Genet 2012;2:15. https:\/\/doi.org\/10.5496\/wjmg.v2.i3.15.","DOI":"10.5496\/wjmg.v2.i3.15"},{"key":"2026040923062353328_j_mr-2024-0060_ref_029","unstructured":"Ali, EZ, Yakob, Y, Md Desa, N, Ishak, T, Zakaria, Z, Ngu, LK, et al.. Molecular analysis of fragile X syndrome (FXS) among Malaysian patients with developmental disability. Malays J Pathol 2017;39:99\u2013106."},{"key":"2026040923062353328_j_mr-2024-0060_ref_030","doi-asserted-by":"crossref","unstructured":"Saha, S, Karmakar, P, Chatterjee, C, Banerjee, D, Das, S, Dasgupta, UB. Fragile X syndrome in Calcutta, India. Ann Clin Biochem 2001;38:264\u201371. https:\/\/doi.org\/10.1258\/0004563011900498.","DOI":"10.1258\/0004563011900498"},{"key":"2026040923062353328_j_mr-2024-0060_ref_031","unstructured":"Baskaran, S, Naseerullah, MK, Manjunatha, KR, Chetan, GK, Arthi, R, Rao, GV, et al.. Triplet repeat polymorphism & fragile X syndrome in the Indian context. Indian J Med Res 1998;107:29\u201336."},{"key":"2026040923062353328_j_mr-2024-0060_ref_032","unstructured":"Jain, U, Verma, IC, Kapoor, AK. Prevalence of fragile X(A) syndrome in mentally retarded children at a genetics referral centre in Delhi, India. Indian J Med Res 1998;108:12\u20136."},{"key":"2026040923062353328_j_mr-2024-0060_ref_033","doi-asserted-by":"crossref","unstructured":"Sharma, D, Gupta, M, Thelma, BK. Expansion mutation frequency and CGG\/GCC repeat polymorphism inFMR1 andFMR2 genes in an Indian population. Genet Epidemiol 2001;20:129\u201344. https:\/\/doi.org\/10.1002\/1098-2272(200101)20:1<129::aid-gepi11>3.0.co;2-2.","DOI":"10.1002\/1098-2272(200101)20:1<129::AID-GEPI11>3.0.CO;2-2"},{"key":"2026040923062353328_j_mr-2024-0060_ref_034","doi-asserted-by":"crossref","unstructured":"Pandey, UB, Phadke, S, Mittal, B. Molecular screening of FRAXA and FRAXE in Indian patients with unexplained mental retardation. Genet Test 2002;6:335\u20139. https:\/\/doi.org\/10.1089\/10906570260471903.","DOI":"10.1089\/10906570260471903"},{"key":"2026040923062353328_j_mr-2024-0060_ref_035","doi-asserted-by":"crossref","unstructured":"Muthuswamy, S, Dean, D, Agarwal, S. Molecular screening of intellectually disabled patients and those with premature ovarian failure for CGG repeat expansion at FMR1 locus: implication of combined triplet repeat primed polymerase chain reaction and methylation-specific polymerase chain reaction analysis. Neurol India 2016;64:1175. https:\/\/doi.org\/10.4103\/0028-3886.193786.","DOI":"10.4103\/0028-3886.193786"},{"key":"2026040923062353328_j_mr-2024-0060_ref_036","unstructured":"Karunasagar, A, Pandit, L, Kumar, S, Karunasagar, I, Karunasagar, I. Use of methylation sensitive polymerase chain reaction for detection of fragile X full mutation & carrier state in males. Indian J Med Res 2005;122:429\u201333."},{"key":"2026040923062353328_j_mr-2024-0060_ref_037","doi-asserted-by":"crossref","unstructured":"Kabra, M, Sharma, D, Singh, D, Dabral, A, Thelma, B, Kalra, V, et al.. Fragile X screening for FRAXA and FRAXE mutations using PCR based studies: results of a five year study. Indian J Hum Genet 2006;12:17. https:\/\/doi.org\/10.4103\/0971-6866.25297.","DOI":"10.4103\/0971-6866.25297"},{"key":"2026040923062353328_j_mr-2024-0060_ref_038","unstructured":"Bhowmik Adacasackm, DA. Screening for fragile X syndrome among neurobehavioural patients from Kolkata, Eastern India. Clin Diagn Res 2009;3:1266\u201373."},{"key":"2026040923062353328_j_mr-2024-0060_ref_039","doi-asserted-by":"crossref","unstructured":"Katikala, L, Guruju, MR, Madireddi, S, Vallamkonda, O, Vallamkonda, N, Persha, A, et al.. Distribution of CGG\/GCC repeats at the FMR1 and FMR2 genes in an Indian population with mental retardation of unknown etiology. Genet Test Mol Biomarkers 2011;15:281\u20134. https:\/\/doi.org\/10.1089\/gtmb.2010.0167.","DOI":"10.1089\/gtmb.2010.0167"},{"key":"2026040923062353328_j_mr-2024-0060_ref_040","doi-asserted-by":"crossref","unstructured":"Dean, DD, Agarwal, S, Muthuswamy, S. Fragile X molecular investigation and genetic counseling of intellectual disability\/developmental delay patients in an Indian scenario. Expert Rev Mol Diagn 2019;19:641\u20139. https:\/\/doi.org\/10.1080\/14737159.2019.1622416.","DOI":"10.1080\/14737159.2019.1622416"},{"key":"2026040923062353328_j_mr-2024-0060_ref_041","doi-asserted-by":"crossref","unstructured":"Indhumathi, N, Singh, D, Chong, SS, Thelma, BK, Arabandi, R, Srisailpathy, CRS. Fragile X CGG repeat variation in Tamil Nadu, South India: a comparison of radioactive and methylation-specific polymerase chain reaction in CGG repeat sizing. Genet Test Mol Biomarkers 2012;16:113\u201322. https:\/\/doi.org\/10.1089\/gtmb.2011.0102.","DOI":"10.1089\/gtmb.2011.0102"},{"key":"2026040923062353328_j_mr-2024-0060_ref_042","doi-asserted-by":"crossref","unstructured":"Nagarathinam, I, Chong, SS, Thelma, BK, Justin Margret, J, Venkataraman, V, Natarajan Padmavathy, K, et al.. FMR1 gene CGG repeat distribution among the three individual cohorts with intellectual disability, autism, and primary ovarian insufficiency from Tamil Nadu, Southern India. Adv Genet 2021;2. https:\/\/doi.org\/10.1002\/ggn2.10048.","DOI":"10.1002\/ggn2.10048"},{"key":"2026040923062353328_j_mr-2024-0060_ref_043","doi-asserted-by":"crossref","unstructured":"Meraj, N, Yasin, M, Rehman, ZU, Tahir, H, Jadoon, H, Khan, N, et al.. Fragile X premutation carrier screening in Pakistani preconception women in primary care consultation. BMC Wom Health 2022;22:57. https:\/\/doi.org\/10.1186\/s12905-022-01632-1.","DOI":"10.1186\/s12905-022-01632-1"},{"key":"2026040923062353328_j_mr-2024-0060_ref_044","doi-asserted-by":"crossref","unstructured":"Kanwal, M, Alyas, S, Afzal, M, Mansoor, A, Abbasi, R, Tassone, F, et al.. Molecular diagnosis of fragile X syndrome in subjects with intellectual disability of unknown origin: implications of its prevalence in regional Pakistan. PLoS One 2015;10:e0122213. https:\/\/doi.org\/10.1371\/journal.pone.0122213.","DOI":"10.1371\/journal.pone.0122213"},{"key":"2026040923062353328_j_mr-2024-0060_ref_045","doi-asserted-by":"crossref","unstructured":"Chandrasekara, CHWMRB, Wijesundera, WSS, Perera, HN, Chong, SS, Rajan-Babu, IS. Cascade screening for fragile X syndrome\/CGG repeat expansions in children attending special education in Sri Lanka. PLoS One 2015;10:e0145537. https:\/\/doi.org\/10.1371\/journal.pone.0145537.","DOI":"10.1371\/journal.pone.0145537"},{"key":"2026040923062353328_j_mr-2024-0060_ref_046","doi-asserted-by":"crossref","unstructured":"Bailey, DB, Raspa, M, Bishop, E, Holiday, D. No change in the age of diagnosis for fragile X syndrome: findings from a national parent survey. Pediatrics 2009;124:527\u201333. https:\/\/doi.org\/10.1542\/peds.2008-2992.","DOI":"10.1542\/peds.2008-2992"},{"key":"2026040923062353328_j_mr-2024-0060_ref_047","doi-asserted-by":"crossref","unstructured":"Mirza, I, Tareen, A, Davidson, LL, Rahman, A. Community management of intellectual disabilities in Pakistan: a mixed methods study. J Intellect Disabil Res 2009;53:559\u201370. https:\/\/doi.org\/10.1111\/j.1365-2788.2009.01176.x.","DOI":"10.1111\/j.1365-2788.2009.01176.x"},{"key":"2026040923062353328_j_mr-2024-0060_ref_048","doi-asserted-by":"crossref","unstructured":"Tassone, F, Iong, K, Tong, TH, Lo, J, Gane, LW, Berry-Kravis, E, et al.. FMR1 CGG allele size and prevalence ascertained through newborn screening in the United States. Genome Med 2012;4:100. https:\/\/doi.org\/10.1186\/gm401.","DOI":"10.1186\/gm401"},{"key":"2026040923062353328_j_mr-2024-0060_ref_049","doi-asserted-by":"crossref","unstructured":"Ciobanu, CG, Nuc\u0103, I, Popescu, R, Antoci, LM, Caba, L, Ivanov, AV, et al.. Narrative review: update on the molecular diagnosis of fragile X syndrome. Int J Mol Sci 2023;24:9206. https:\/\/doi.org\/10.3390\/ijms24119206.","DOI":"10.3390\/ijms24119206"},{"key":"2026040923062353328_j_mr-2024-0060_ref_050","doi-asserted-by":"crossref","unstructured":"Qin, DH. Next-generation sequencing and its clinical application. Cancer Biol Med 2019;16:4\u201310. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2018.0055.","DOI":"10.20892\/j.issn.2095-3941.2018.0055"},{"key":"2026040923062353328_j_mr-2024-0060_ref_051","doi-asserted-by":"crossref","unstructured":"Sherman, S, Pletcher, BA, Driscoll, DA. Fragile X syndrome: diagnostic and carrier testing. Genet Med 2005;7:584\u20137. https:\/\/doi.org\/10.1097\/01.gim.0000182468.22666.dd.","DOI":"10.1097\/01.GIM.0000182468.22666.dd"},{"key":"2026040923062353328_j_mr-2024-0060_ref_052","unstructured":"Consensus of the Fragile X Clinical and Research Consortium. National fragile X foundation. Medications for Individuals with Fragile X Syndrome; 2022. https:\/\/fragilex.org\/wp-content\/uploads\/Medications-Treatment-Recommendation.pdf [Accessed 11 Jun 2024]."},{"key":"2026040923062353328_j_mr-2024-0060_ref_053","unstructured":"Dr. Michael Tranfaglia. Medication reference guide. https:\/\/www.fraxa.org\/medication-reference-guide\/ [Accessed 11 Jun 2024]."},{"key":"2026040923062353328_j_mr-2024-0060_ref_054","doi-asserted-by":"crossref","unstructured":"Protic, D, Salcedo-Arellano, MJ, Dy, JB, Potter, LA, Hagerman, RJ. New targeted treatments for fragile X syndrome. Curr Pediatr Rev 2019;15:251\u20138. https:\/\/doi.org\/10.2174\/1573396315666190625110748.","DOI":"10.2174\/1573396315666190625110748"},{"key":"2026040923062353328_j_mr-2024-0060_ref_055","unstructured":"Jonathan Picker, VS. Behavioral challenges in fragile X syndrome [Internet]. 2011. https:\/\/fragilex.org\/wp-content\/uploads\/NFXF-recommendations-behavioral.pdf [Accessed 2024 Jun 11]."},{"key":"2026040923062353328_j_mr-2024-0060_ref_056","unstructured":"Anne Hoffmann, KLC. Language in fragile X syndrome what to expect and implications for assessment and intervention. [Internet]; 2023. https:\/\/fragilex.org\/wp-content\/uploads\/fxcrc-language-fxs.pdf [Accessed 11 Jun 2024]."},{"key":"2026040923062353328_j_mr-2024-0060_ref_057","unstructured":"Marcia Braden KRJZSHEBK. Educational recommendations for fragile X syndrome - elementary school. [Internet]; 2012. https:\/\/fragilex.org\/wp-content\/uploads\/Educational-Recommendations-for-Fragile-X-Syndrome-Elementary-School.pdf [Accessed 11 Jun 2024]."},{"key":"2026040923062353328_j_mr-2024-0060_ref_058","doi-asserted-by":"crossref","unstructured":"Berry\u2010Kravis, E, Potanos, K. Psychopharmacology in fragile X syndrome\u2014present and future. Ment Retard Dev Disabil Res Rev 2004;10:42\u20138. https:\/\/doi.org\/10.1002\/mrdd.20007.","DOI":"10.1002\/mrdd.20007"},{"key":"2026040923062353328_j_mr-2024-0060_ref_059","doi-asserted-by":"crossref","unstructured":"Berry-Kravis, E. Disease-targeted treatment translation in fragile X syndrome as a model for neurodevelopmental disorders. J Child Neurol 2022;37:797\u2013812. https:\/\/doi.org\/10.1177\/08830738221089740.","DOI":"10.1177\/08830738221089740"},{"key":"2026040923062353328_j_mr-2024-0060_ref_060","doi-asserted-by":"crossref","unstructured":"Potter, LA, Scholze, DA, Biag, HMB, Schneider, A, Chen, Y, Nguyen, DV, et al.. A randomized controlled trial of sertraline in young children with autism spectrum disorder. Front Psychiatr 2019;10. https:\/\/doi.org\/10.3389\/fpsyt.2019.00810.","DOI":"10.3389\/fpsyt.2019.00810"},{"key":"2026040923062353328_j_mr-2024-0060_ref_061","doi-asserted-by":"crossref","unstructured":"Dy, ABC, Tassone, F, Eldeeb, M, Salcedo\u2010Arellano, MJ, Tartaglia, N, Hagerman, R. Metformin as targeted treatment in fragile X syndrome. Clin Genet 2018;93:216\u201322. https:\/\/doi.org\/10.1111\/cge.13039.","DOI":"10.1111\/cge.13039"},{"key":"2026040923062353328_j_mr-2024-0060_ref_062","doi-asserted-by":"crossref","unstructured":"Jacquemont, S, Hagerman, RJ, Leehey, MA, Hall, DA, Levine, RA, Brunberg, JA, et al.. Penetrance of the fragile X\u2013associated tremor\/ataxia syndrome in a premutation carrier population. JAMA 2004;291:460. https:\/\/doi.org\/10.1001\/jama.291.4.460.","DOI":"10.1001\/jama.291.4.460"},{"key":"2026040923062353328_j_mr-2024-0060_ref_063","doi-asserted-by":"crossref","unstructured":"Hagerman, RJ, Protic, D, Rajaratnam, A, Salcedo-Arellano, MJ, Aydin, EY, Schneider, A. Fragile X-associated neuropsychiatric disorders (FXAND). Front Psychiatr 2018;9:564. https:\/\/doi.org\/10.3389\/fpsyt.2018.00564.","DOI":"10.3389\/fpsyt.2018.00564"},{"key":"2026040923062353328_j_mr-2024-0060_ref_064","doi-asserted-by":"crossref","unstructured":"Allen, EG, Charen, K, Hipp, HS, Shubeck, L, Amin, A, He, W, et al.. Refining the risk for fragile X\u2013associated primary ovarian insufficiency (FXPOI) by FMR1 CGG repeat size. Genet Med 2021;23:1648\u201355. https:\/\/doi.org\/10.1038\/s41436-021-01177-y.","DOI":"10.1038\/s41436-021-01177-y"},{"key":"2026040923062353328_j_mr-2024-0060_ref_065","unstructured":"Randi, J, Hagerman, PJH. Fragile X syndrome and premutation disorders: New developments and treatments (Clinics in Developmental Medicine), Hagerman, RJ, Hagerman, PJ, editors. London: Mac Keith Press; 2020."}],"container-title":["Medical Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/mr-2024-0060\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/mr-2024-0060\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T23:06:44Z","timestamp":1775776004000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/mr-2024-0060\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,29]]},"references-count":65,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,11,29]]},"published-print":{"date-parts":[[2025,4,28]]}},"alternative-id":["10.1515\/mr-2024-0060"],"URL":"https:\/\/doi.org\/10.1515\/mr-2024-0060","relation":{},"ISSN":["2749-9642"],"issn-type":[{"value":"2749-9642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,29]]}}}